1. All Articles

    1-24 of 2626 1 2 3 4 ... 108 109 110 »
    1. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.

      Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.

      Pediatr Blood Cancer. 2017 Apr;64(4):

      Authors: Batra V, Makvandi M, Zuppa AF, Patel N, Elias J, Pryma DA, Maris JM

      Abstract BACKGROUND: Neuroblastoma is a pediatric malignancy, and most tumor cells express the norepinephrine transporter (NET) enabling uptake of NET ligands.

      Read Full Article
      Mentions: MIBG
    2. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

      Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

      Oncotarget. 2017 Jul 04;:

      Authors: Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T

      Abstract Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.

      Read Full Article
    3. Elevated Preoperative Neutrophil-Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors.

      Elevated Preoperative Neutrophil-Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors.

      Ann Surg Oncol. 2017 Jul 17;:

      Authors: Nayak A, McDowell DT, Kellie SJ, Karpelowsky J

      Abstract BACKGROUND: An elevated neutrophil-lymphocyte ratio (NLR) has been shown to indicate poorer prognosis for adults with solid tumors and potentially represents an independent, universal adjunct prognostic factor.

      Read Full Article
    4. Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells.

      Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells.

      J Extracell Vesicles. 2017;6(1):1332941

      Authors: Nakata R, Shimada H, Fernandez GE, Fanter R, Fabbri M, Malvar J, Zimmermann P, DeClerck YA

      Read Full Article
      Mentions: MYCN Bone Marrow
    5. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    6. Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.

      Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.

      Clin Cancer Res. 2017 Jul 14;:

      Authors: Van Roy N, Van der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K

      Read Full Article
      Mentions: MYCN ATRX
    7. Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.

      Moringa isothiocyanate complexed with α-cyclodextrin: a new perspective in neuroblastoma treatment.

      BMC Complement Altern Med. 2017 Jul 14;17(1):362

      Authors: Giacoppo S, Iori R, Rollin P, Bramanti P, Mazzon E

      Abstract BACKGROUND: Several lines of evidence suggest the consume of natural products for cancer prevention or treatment. In particular, isothiocyanates (ITCs) exerting anti-cancer properties, have received great interest as potential chemotherapeutic agents.

      Read Full Article
      Mentions: Treatment LDH
    8. Biodistribution and dosimetry of (18)F-Meta Fluorobenzyl Guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies.

      Biodistribution and dosimetry of (18)F-Meta Fluorobenzyl Guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies.

      J Nucl Med. 2017 Jul 13;:

      Authors: Pandit-Taskar N, Zanzonico PB, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko SK, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S

      Read Full Article
      Mentions: Imaging MIBG
    9. New potential treatment for aggressive types of childhood cancer

      New potential treatment for aggressive types of childhood cancer

      A combination of substances that impacts chemical modifications in the DNA of tumours and triggers the tumours to differentiate into harmless nerve cells could represent a new method of treating aggressive forms of neuroblastoma. The new method has been proposed by researchers at Karolinska Institutet, after studies using mice showed that the combination treatment resulted in a significant suppression in tumour growth.

      Read Full Article
      Mentions: Treatment
    10. RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.

      RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.

      Oncol Lett. 2017 Jul;14(1):860-866

      Authors: Grèze V, Kanold J, Chambon F, Halle P, Gremeau AS, Rives N, Rouel N, Pereira B, Tchirkov A, Brugnon F

      Read Full Article
      Mentions: PHOX2B
    11. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

      Proc Natl Acad Sci U S A. 2017 Jul 10;:

      Authors: Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J

      Read Full Article
      Mentions: Treatment MYCN
    12. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      Cancer. 2017 Jul 11;:

      Authors: Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG

      Read Full Article
      Mentions: Staging COG MYCN
    13. Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.

      Metabolic syndrome induced by anticancer treatment in childhood cancer survivors.

      Ann Pediatr Endocrinol Metab. 2017 Jun;22(2):82-89

      Authors: Chueh HW, Yoo JH

      Abstract The number of childhood cancer survivors is increasing as survival rates improve. However, complications after treatment have not received much attention, particularly metabolic syndrome.

      Read Full Article
      Mentions: Treatment
    14. Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

      Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jul 07;:

      Authors: Stone A, Novetsky Friedman D, Worgall S, Kushner BH, Wolden S, Modak S, LaQuaglia MP, Wu X, Cheung NK, Sklar CA

      Abstract BACKGROUND: Children with high-risk neuroblastoma are exposed to multimodality therapies early in life and survivors confront late therapy-related toxicities.

      Read Full Article
    15. Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   Histiocytosis;   HRAS Gene Mutation;   KRAS Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory
    16. Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations

      Conditions :   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   ALK Gene Translocation;   Histiocytosis;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation;   ROS1 Gene Translocation;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified July 2017

      Read Full Article
      Mentions: Refractory ALK
    17. Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors

      SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to entrectinib for “treatment of NTRK fusion-positive solid tumors.” NTRK fusions are molecular alterations that occur in a broad variety of adult and pediatric solid tumor types. Entrectinib is the company’s investigational, orally available, CNS-active tyrosine kinase inh

      Read Full Article
      Mentions: Treatment ALK
    18. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      BMC Immunol. 2017 Jul 07;18(1):36

      Authors: Mou W, Han W, Ma X, Wang X, Qin H, Zhao W, Ren X, Chen X, Yang W, Cheng H, Wang X, Zhang H, Ni X, Wang H, Gui J

      Abstract BACKGROUND: Previous studies have shown that γδ TFH cells are capable of modulating antibody production in immunized and infected mouse model.

      Read Full Article
      Mentions: Antibody
    19. Upregulation of LYAR induces neuroblastoma cell proliferation and survival.

      Upregulation of LYAR induces neuroblastoma cell proliferation and survival.

      Cell Death Differ. 2017 Jul 07;:

      Authors: Sun Y, Atmadibrata B, Yu D, Wong M, Liu B, Ho N, Ling D, Tee AE, Wang J, Mungrue IN, Liu PY, Liu T

      Abstract The N-Myc oncoprotein induces neuroblastoma by regulating gene transcription and consequently causing cell proliferation.

      Read Full Article
    20. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

      Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

      Oncoimmunology. 2017;6(6):e1320625

      Authors: Hoseini SS, Dobrenkov K, Pankov D, Xu XL, Cheung NV

      Abstract Chimeric antigen receptors (CAR) and bispecific antibodies (BsAb) are two powerful immunotherapy approaches for retargeting lymphocytes toward cancer cells. Despite their success in lymphoblastic leukemia, solid tumors have been more recalcitrant.

      Read Full Article
    1-24 of 2626 1 2 3 4 ... 108 109 110 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. INBRACED

    See all INBRACED articles
  4. Organizations in the News

    1. (77 articles) COG
    2. (22 articles) SIOP
    3. (22 articles) NANT
    4. (18 articles) SIOPEN
    5. (17 articles) MSKCC
    6. (14 articles) GPOH
    7. (13 articles) INRG
    8. (11 articles) NMTRC
  5. Locations in the News

    1. (8 articles) Other Countries
  6. Researches in the News

    1. (202 articles) MYCN
    2. (191 articles) Immunotherapy
    3. (121 articles) Antibody
    4. (105 articles) ALK
    5. (74 articles) T-Cells
    6. (71 articles) Imaging
    7. (55 articles) Bone Marrow
    8. (45 articles) ASCO
    9. (42 articles) Metastasis
    10. (27 articles) PD-1
  7. General Informations in the News

    1. (363 articles) Treatment
    2. (21 articles) Staging
    3. (5 articles) Hearing Loss
  8. Treatments in the News

    1. (94 articles) Surgery
    2. (78 articles) Refractory
    3. (77 articles) Chemotherapy
    4. (70 articles) MIBG
    5. (65 articles) Stem Cell Transplant
    6. (58 articles) Relapse
    7. (57 articles) Radiotherapy
    8. (19 articles) Diagnostics
    9. (18 articles) Side Effects
    10. (9 articles) Targetted Therapy